/BLLN
BLLN Stock - BillionToOne, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$102.60+7.43%
+$7.10 (+7.43%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.44
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+32.9%upside
Target: $136.36
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BLLN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$101.57 – $103.63
TARGET (TP)$136.40
STOP LOSS$94.39
RISK/REWARD1:4.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.00
52W High$138.70
52W Low$88.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $152.58M | $71.73M |
| Gross Profit | $80.92M | $17.31M |
| Gross Margin | 53.0% | 24.1% |
| Operating Income | $-47,146,000 | $-69,495,000 |
| Net Income | $-41,570,000 | $-82,683,000 |
| Net Margin | -27.2% | -115.3% |
| EPS | $-0.93 | $-1.85 |
Company Overview
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
60%
Hold / Neutral
2
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish2 Neutral/Bearish
Price Targets
$139
Average Target
↑ 35.2% Upside
Now
$110
Low
$139
Average
$160
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | William Blair | Initiation | Outperform | - |
| December 1st 2025 | Jefferies | Initiation | Hold | $117 |
| December 1st 2025 | JP Morgan | Initiation | Overweight | $150 |
| December 1st 2025 | Piper Sandler | Initiation | Overweight | $150 |
| December 1st 2025 | Stifel | Initiation | Buy | $145 |
| December 1st 2025 | Wells Fargo | Initiation | Equal Weight | $110 |
| December 1st 2025 | BTIG Research | Initiation | Buy | $160 |
Earnings History & Surprises
BLLNBeat Rate
0%
Last 1 quarters
Avg Surprise
-28.3%
EPS vs Estimate
Beats / Misses
0/1
Last 12 quarters
Latest EPS
$0.10
Q4 2025
EPS Surprise History
Q4 25
-28.3%
$0.10vs$0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $0.07 | — | — | — |
Q4 2025 | Dec 9, 2025 | $0.14 | $0.10 | -28.3% | ✗ MISS |
Latest News
BillionToOne shares are trading lower after JP Morgan lowered its price target from $150 to $145 on the stock.
📉 NegativeBenzinga•Dec 10, 2025, 05:47 PM
JP Morgan Maintains Overweight on BillionToOne, Lowers Price Target to $145
➖ NeutralBenzinga•Dec 10, 2025, 04:03 PM
BTIG Reiterates Buy on BillionToOne, Maintains $160 Price Target
📈 PositiveBenzinga•Dec 10, 2025, 10:25 AM
BLLN stock has given up its prior loss. BillionToOne shares were trading lower after the company reported mixed Q3 financial results.
➖ NeutralBenzinga•Dec 9, 2025, 09:52 PM
BillionToOne shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Dec 9, 2025, 09:21 PM
CORRECTION: BillionToOne Sees Q4 Revenue $84M-$90M, FY25 Revenue $293M-$299M
➖ NeutralBenzinga•Dec 9, 2025, 09:08 PM
BillionToOne Q3 EPS $0.10 Misses $0.16 Estimate, Sales $83.500M Beat $82.814M Estimate
➖ NeutralBenzinga•Dec 9, 2025, 09:06 PM
Piper Sandler Initiates Coverage On BillionToOne with Overweight Rating, Announces Price Target of $150
📈 PositiveBenzinga•Dec 1, 2025, 05:54 PM
Stifel Initiates Coverage On BillionToOne with Buy Rating, Announces Price Target of $145
📈 PositiveBenzinga•Dec 1, 2025, 04:13 PM•Also:
Wells Fargo Initiates Coverage On BillionToOne with Equal-Weight Rating, Announces Price Target of $110
➖ NeutralBenzinga•Dec 1, 2025, 02:21 PM
JP Morgan Initiates Coverage On BillionToOne with Overweight Rating, Announces Price Target of $150
📈 PositiveBenzinga•Dec 1, 2025, 01:52 PM
Jefferies Initiates Coverage On BillionToOne with Hold Rating, Announces Price Target of $117
➖ NeutralBenzinga•Dec 1, 2025, 01:06 PM•Also:
BTIG Initiates Coverage On BillionToOne with Buy Rating, Announces Price Target of $160
📈 PositiveBenzinga•Dec 1, 2025, 11:28 AM
BillionToOne Shares Resume Trade
➖ NeutralBenzinga•Nov 6, 2025, 06:08 PM
BillionToOne IPO Opens For Trade At $100/Share; IPO Priced At $60/Share
📈 PositiveBenzinga•Nov 6, 2025, 05:42 PM
BillionToOne Shares Indicating $92.25
📈 PositiveBenzinga•Nov 6, 2025, 03:54 PM
BillionToOne IPO Indicating $85/Share On 82K Shares; IPO Priced At $60/Share on 4,551,100 Shares
📈 PositiveBenzinga•Nov 6, 2025, 03:23 PM
Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation
➖ NeutralBenzinga•Nov 6, 2025, 03:10 PM
Reported Earlier, BillionToOne Prices Upsized Initial Public Offering Of 4,551,100 Class A Common Shares At $60.00 Each For Expected Gross Proceeds Of $273.1M
📈 PositiveBenzinga•Nov 6, 2025, 08:22 AM
Frequently Asked Questions about BLLN
What is BLLN's current stock price?
BillionToOne, Inc. (BLLN) is currently trading at $102.60 per share. The stock has moved +7.43% today.
What is the analyst price target for BLLN?
The average analyst price target for BLLN is $136.40, based on 1 analyst.
What sector is BillionToOne, Inc. in?
BillionToOne, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is BLLN's market cap?
BillionToOne, Inc. has a market capitalization of $4.70 billion, making it a mid-cap company.
Does BLLN pay dividends?
No, BillionToOne, Inc. does not currently pay a dividend to shareholders.